Technology
Celltrix has developed Credurance - a biorestoring technology that enables the skin to regenerate collagen, which is a substance lacking in human wrinkles as people age. By injecting Credurance into the facial tissue an immediate filling effect is achieved and the surrounding cells are presented to a matrix suitable for cell growth. As the cells grow on and inside the matrix, they produce natural collagen, which gradually replaces the matrix.
Value Proposition
The market for cosmetic procedures continues to develop rapidly, and in particular in the western world the elderly are financially strong and focused on looking healthy and attractive. Credurance promises to provide an immediate solution to wrinkles as well as a long lasting result using a biodegradable product.
Proof of concept has been made and Celltrix is currently completing the clinical trial (phase III).
Additional information
-
Management: Björn Forsman (CEO)
-
-
-
Co-investors: Novo, Malmöhus Invest, Lumitec
-